Join to View Full Profile
3901 Rainbow BlvdMail Stop 4033Kansas City, KS 66160
Phone+1 913-588-3600
Fax+1 913-588-3663
Dr. Shen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Xinglei Shen is a Radiation Oncology specialist based in Kansas City, KS. He completed his residency in Radiation Oncology at Sidney Kimmel Medical College at Thomas Jefferson University/TJUH following his graduation from the University of Pittsburgh School of Medicine in 2007. Presently, he serves as an Associate Professor at The University of Kansas Medical Center. Dr. Shen specializes in the treatment of genitourinary cancer. He has numerous publications in prominent medical journals about financial toxicity in radiation oncology and prostate cancer treatment. In addition, Dr. Shen has been a principal investigator and contact for several clinical trials which include research on treatments for high-risk prostate cancer and bladder cancer.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Radiation Oncology, 2008 - 2012
UPMC Medical EducationInternship, Transitional Year, 2007 - 2008
University of Pittsburgh School of MedicineClass of 2007
Certifications & Licensure
CO State Medical License 2023 - 2027
IA State Medical License 2024 - 2027
MO State Medical License 2015 - 2027
KS State Medical License 2012 - 2026
NM State Medical License 2023 - 2026
PA State Medical License 2007 - 2012
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Clinical Trials
- Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
- Ultra-hypofractionated Radiation in Prostate Cancer Start of enrollment: 2018 Mar 22
- Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Start of enrollment: 2023 Nov 20
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Changes over time in total Medicare costs for active surveillance versus radiotherapy in prostate cancer.Jiaye Shen, Ronald C Chen, Mutlay Sayan, Xinglei Shen, Aaron J Katz
International Journal of Radiation Oncology, Biology, Physics. 2026-02-14 - A Pilot Trial of Two-Fraction Stereotactic Body Radiation Therapy for Localized Prostate Cancer.Xinglei Shen, Matthew Chen, Ying Cao, Amanda Schroeder, Leah Miller
Cureus. 2025-12-01 - A few-shot u-net learning framework for fast and accurate three-dimensional dose prediction in radiotherapy.Zhong Chen, Wangyao Li, Xinglei Shen, Ronald C Chen, Yuting Lin
Physica Medica. 2025-11-01
Press Mentions
Curative-Intent Approaches to Node-Positive Prostate CancerFebruary 4th, 2026- Good Cancer Control, Survival with SBRT for Limited Metastatic/Progressive DiseaseOctober 13th, 2025
Brachytherapy Reduced Death Rates in High-Risk Prostate Cancer Patients, Analysis FindsJanuary 26th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
